重叠综合征

Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899-909.

• 摘要

Spath M, Schroder M, Schlotter-Weigel B, et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol. 2004;251:859-864.

• 摘要

Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841-1847.

• 摘要

1.  Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899-909.

• 摘要

2.  Spath M, Schroder M, Schlotter-Weigel B, et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol. 2004;251:859-864.

• 摘要

3.  Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:501-508.

• 摘要

4.  Cortes S, Clemente-Coelho P. Nailfold capillaroscopy in the evaluation of Raynaud's phenomenon and undifferentiated connective tissue disease [in Portuguese]. Acta Reumatol Port. 2008;33:203-209.

• 摘要

5.  Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21:313-320.

• 摘要

6.  Imbert-Masseau A, Hamidou M, Agard C, et al. Antisynthetase syndrome. Joint Bone Spine. 2003;70:161-168.

• 摘要

7.  Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam, the Netherlands: Elsevier; 1987:33-40.

8.  Kasukawa R, Tojo T, Miyawaki S, et al. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam, the Netherlands: Elsevier; 1987:41-47.

9.  Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44:145-150.

• 全文
• 摘要

10.  Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841-1847.

• 摘要

11.  Harding SE, Tingey PC, Pope J, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 1998;(2):CD000956.

• 全文
• 摘要

12.  Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-2985.

• 全文
• 摘要

13.  Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-3993.

• 全文
• 摘要

14.  Hall S, Hanrahan P. Muscle involvement of mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31:509-517,vii.

• 摘要

15.  Fox RI, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5(suppl 1):S31-S36.

• 摘要

16.  Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus. 2005;14:822-826.

• 摘要

17.  Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34:2417-2422.

• 摘要

18.  Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.

• 全文
• 摘要

19.  Marotta H, Montisci R, Tiso F, et al. Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases [in Italian]. Reumatismo. 2007;59:299-303.

• 摘要

20.  Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-359.

• 全文
• 摘要

21.  McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.

• 全文
• 摘要

22.  Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48:1433-1437.

• 摘要

23.  Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130:182-189.

• 全文
• 摘要

24.  Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521-531.

• 全文
• 摘要

25.  Sauty A, Rochat T, Schoch OD, et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J. 1997;10:2907-2912.

• 全文
• 摘要

26.  Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-328.

• 摘要

27.  Linnik MD, Hu JZ, Heilbrunn KR, et al; LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1129-1137.

• 全文
• 摘要